JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB238819

Anti-B3GNT5 antibody

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Polyclonal B3GNT5 antibody. Suitable for IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Recombinant Fragment Protein within Human Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase aa 50-350.

View Alternative Names

Lactotriaosylceramide synthase, Lc(3)Cer synthase, Lc3 synthase, BGnT-5, Beta3Gn-T5, B3GNT5

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B3GNT5 antibody (AB238819)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B3GNT5 antibody (AB238819)

Paraffin-embedded human lung tissue stained for B3GNT5 using ab238819 at 1/100 dilution in immunohistochemical analysis.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B3GNT5 antibody (AB238819)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-B3GNT5 antibody (AB238819)

Paraffin-embedded human testis tissue stained for B3GNT5 using ab238819 at 1/100 dilution in immunohistochemical analysis.

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

Recombinant Fragment Protein within Human Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase aa 50-350. The exact immunogen used to generate this antibody is proprietary information.

Q9BYG0

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/20 - 1/200", "IHCP-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
Purity greater than 95%.
Storage buffer
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

B3GNT5 also known as UDP-GlcNAc:betaGal beta-13-N-acetylglucosaminyltransferase 5 functions primarily as a glycosyltransferase enzyme. It has a molecular mass of approximately 42 kDa. B3GNT5 is expressed in various tissues including the brain and muscle and is critical for synthesizing poly-N-acetyllactosamine which is important for cellular communication and adhesion processes.
Biological function summary

The B3GNT5 enzyme facilitates the addition of N-acetylglucosamine in a beta-13 linkage to galactose residues on glycoconjugates. It contributes significantly to glycan biosynthesis and may participate in forming part of glycoprotein and glycolipid complexes. These glycoconjugates impact cell signaling migration and cell-cell interactions. The precise formation of glycoconjugates supports critical cellular functions influencing processes like immune response and cellular differentiation.

Pathways

B3GNT5 plays a role in the complex glycosylation pathway. This pathway involves the assembly and modification of glycan structures essential for protein stability and function. B3GNT5 interacts with other enzymes such as B3GNT2 impacting the regulation of glycan chains. The pathway affects key processes like the production of selectin ligands which are vital for leukocyte trafficking and inflammatory responses.

Abnormalities in B3GNT5 expression or function can link to cancer progression and congenital disorders of glycosylation. Changes in its activity influence the expression and remodeling of glycans potentially affecting tumor cell interaction and metastasis. In some congenital glycosylation disorders defective glycan synthesis might relate to developmental issues where B3GNT5 and its glycan partner proteins play a role in ensuring proper cellular development and function.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Beta-1,3-N-acetylglucosaminyltransferase that plays a key role in the synthesis of lacto- or neolacto-series carbohydrate chains on glycolipids, notably by participating in biosynthesis of HNK-1 and Lewis X carbohydrate structures. Has strong activity toward lactosylceramide (LacCer) and neolactotetraosylceramide (nLc(4)Cer; paragloboside), resulting in the synthesis of Lc(3)Cer and neolactopentaosylceramide (nLc(5)Cer), respectively. Probably plays a central role in regulating neolacto-series glycolipid synthesis during embryonic development.
See full target information Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

EBioMedicine 66:103301 PubMed33813137

2021

A circular network of coregulated sphingolipids dictates lung cancer growth and progression.

Applications

Unspecified application

Species

Unspecified reactive species

Qiong Meng,Xueting Hu,Xinbao Zhao,Xiangzhan Kong,Ya-Ming Meng,Yitian Chen,Liangping Su,Xue Jiang,Xiaoyi Qiu,Cheng Huang,Chao Liu,Minghui Wang,Ping-Pui Wong

Cell reports. Medicine 2:100166 PubMed33521697

2021

A distinct innate immune signature marks progression from mild to severe COVID-19.

Applications

Unspecified application

Species

Unspecified reactive species

Stéphane Chevrier,Yves Zurbuchen,Carlo Cervia,Sarah Adamo,Miro E Raeber,Natalie de Souza,Sujana Sivapatham,Andrea Jacobs,Esther Bachli,Alain Rudiger,Melina Stüssi-Helbling,Lars C Huber,Dominik J Schaer,Jakob Nilsson,Onur Boyman,Bernd Bodenmiller
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB176689

Anti-ZNF384 antibody

Immunoprecipitation - Anti-ZNF384 antibody (AB176689)

  • 5
  • 1
Primary Antibodies

AB32445

Anti-Bad antibody [Y208]

BOND RX™ Validated|20ul selling size|RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Bad antibody [Y208] (AB32445)

  • 4
  • 13
Primary Antibodies

AB185645

Anti-Caspase-6/CASP-6 antibody [EPR18043]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-Caspase-6/CASP-6 antibody [EPR18043] (AB185645)

  • 0
  • 1
Primary Antibodies

AB180522

Anti-EDEM2 antibody [EPR14043-24]

RabMAb|Recombinant

Western blot - Anti-EDEM2 antibody [EPR14043-24] (AB180522)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com